{"product_id":"amhc-promoter-driven-sacas9-crispr-aav-aav-amhc-sacas9-bhv21600532","title":"aMHC promoter driven saCas9\/CRISPR AAV (AAV-aMHC-saCas9)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eaMHC promoter driven saCas9\/CRISPR AAV (AAV-aMHC-saCas9) is an AAV vector under the αMHC promoter that delivers \u003cstrong\u003eSaCas9\u003c\/strong\u003e to mammalian cells. Researchers commonly use this vector for in vivo crispr genome editing.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePromoter:\u003c\/strong\u003e αMHC — α-myosin heavy chain promoter; cardiomyocyte-restricted, postnatal.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePayload:\u003c\/strong\u003e SaCas9 — Staphylococcus aureus Cas9 nuclease (~3.2 kb CDS); recognizes NNGRRT PAM and is compact enough to be packaged with regulatory elements in a single AAV.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGenome backbone:\u003c\/strong\u003e Recombinant AAV (single-stranded unless explicitly noted as scAAV) flanked by AAV2 ITRs.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eSpCas9 is the Streptococcus pyogenes type II CRISPR-associated nuclease, the most widely characterized Cas9 variant. SpCas9 directs sequence-specific DNA cleavage when paired with a single-guide RNA (sgRNA) and an NGG protospacer-adjacent motif (PAM) in the target. The SpCas9 coding sequence (~4.2 kb) often necessitates a dual-AAV delivery strategy when paired with sgRNA cassettes and regulatory elements.\u003c\/p\u003e\u003cp\u003eAAV-delivered SpCas9 is widely used for in vivo and ex vivo genome editing across many tissue types.\u003c\/p\u003e\u003cp\u003eThe αMHC promoter — α-myosin heavy chain promoter; cardiomyocyte-restricted, postnatal — drives expression of the payload from the AAV cassette in this product. Promoter–capsid combinations together determine where and at what level the payload is expressed.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eAAV-delivered SaCas9 has enabled tissue-specific in vivo genome editing for liver, muscle, and CNS targets.\u003c\/li\u003e\n\u003cli\u003eNewer CRISPR variants (base editors, prime editors) are being adapted for AAV delivery, with active work on managing payload size.\u003c\/li\u003e\n\u003cli\u003eAAV vector engineering — including capsid evolution, capsid shuffling, and rational design — continues to expand the spectrum of accessible tissues and cell types.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eTissue-specific in vivo genome editing using cell-type promoters.\u003c\/li\u003e\n\u003cli\u003eLoss-of-function studies in adult animals without germline manipulation.\u003c\/li\u003e\n\u003cli\u003eMultiplexed editing when paired with appropriate sgRNA cassettes.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eUse this product within experimental designs that include matched controls (capsid, promoter, dose, route) and a transduction validation step before interpreting payload-specific phenotypes.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eConfirm transduction efficiency in the target cell population before drawing payload-specific conclusions; reporter signal alone validates only that the vector reached and expressed in the cells.\u003c\/li\u003e\n\u003cli\u003eMatch AAV dose, capsid, promoter, and route across all conditions when comparing payload to control; differences in any of these confound payload-specific interpretation.\u003c\/li\u003e\n\u003cli\u003eAvoid repeated freeze–thaw cycles of AAV stocks — aliquot upon first thaw.\u003c\/li\u003e\n\u003cli\u003eAAV biology, including tropism, can differ between species, strains, ages, and routes — confirm in your specific system.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- Sources (internal):\n- Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR\/Cas systems. Science. 2013. https:\/\/www.science.org\/doi\/10.1126\/science.1231143\n- Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013. https:\/\/www.science.org\/doi\/10.1126\/science.1232033\n- Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Mol Ther. 2008. https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/fulltext\/S1525-0016(16)33063-5\n--\u003e","brand":"Vector Biolabs","offers":[{"title":"AAV-DJ \/ 1x10^13 GC\/ml \/ 50 µL","offer_id":53286504694125,"sku":"7128","price":495.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/amhc-promoter-driven-sacas9-crispr-aav-aav-amhc-sacas9-bhv21600532","provider":"BioHippo","version":"1.0","type":"link"}